Navigation Links
Sangamo BioSciences Reports Third Quarter 2013 Financial Results
Date:10/23/2013

cial license agreements with collaborators, presentation of data from research collaboration, expected timing for clinical trial data, recognition of revenues under collaboration agreements and the eligibility to receive milestone and other payments under collaboration agreements. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the early stage of ZFP Therapeutic development, uncertainties related to the timing of initiation and completion of clinical trials, whether clinical trial results will validate and support the safety and efficacy of ZFP Therapeutics, and the ability to establish strategic partnerships.  Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo will be able to develop commercially viable gene based therapeutics. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo's operations and business environments. These risks and uncertainties are described more fully in Sangamo's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and Sangamo assumes no obligation to update the forward-looking information contained in this press release.SELECTED CONSOLIDATED FINANCIAL DATA(in thousands, except per share data)(unaudited) Three Months Ended Nine Months Ended September 30,  September 30, 2013201220132012Statement of Operations Data:Revenues:Collaboration agreements

$
4,825$
4,190$  15,065$
9,665Research grants

8827172,1993,058Total revenues

5,7074,90717,26412,723Operating expenses:Research and development

8
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Sangamo BioSciences Announces Closing Of $74.2 Million Public Offering Of Common Stock And Exercise Of Over-Allotment Option
2. Sangamo BioSciences Proposes Public Offering Of Common Stock
3. Biotech Firms Receive Orphan Drug Designations, Release Clinical Data, Achieve Goals, Enter Acquisitions & Forecast Revenues - Research Report on Aegerion, Oncolytics, Merrimack, Sangamo, and PDL
4. Sangamo BioSciences Announces Presentation At The 2013 Wedbush Life Sciences Management Access Conference
5. Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
6. Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference
7. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
8. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
9. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
10. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
11. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... , May 1, 2015 /PRNewswire/ - BioAmber Inc. ... sustainable chemicals, today announced that it has priced an underwritten ... at a price of $9.00 per share, and granted ... purchase up to an additional 585,000 shares of its ... be $35.1 million.  The offering is expected to close on ...
(Date:5/1/2015)... 1, 2015 Albany Molecular Research Inc. (NASDAQ: ... Marth , AMRI,s President and Chief Executive Officer, will ... Health Care Conference on Wednesday, May 13, 2015 at ... of the presentation can be accessed at AMRI,s Investor ... The webcast will be archived for 90 days following ...
(Date:4/30/2015)... , April 30, 2015   Tamir Biotechnology ... today an update on its Ebola antiviral therapy program. ... leading candidates, TMR004, is currently being evaluated and considered ... the battle against Ebola. During the first quarter of ... Leadership Meeting To Accelerate The Evaluation of Potential Treatments ...
(Date:4/30/2015)... 2015 The following is an open letter sent ... Cord Blood Corp (NYSE: CO ) from Jayhawk Capital. ... independent directors of China Cord Blood Corp (" China Cord ... per share from Golden Meditech Holdings Co Ltd ("Golden Med"). ... greatly benefit Golden Med and Mr. Kam, the Chairman of ...
Breaking Biology Technology:BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3AMRI to Present at the Bank of America Merrill Lynch 2015 Health Care Conference 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 2April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 3April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 4April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 5
... 2011 MabVax Therapeutics, Inc., a privately held clinical ... and antibody based therapies to address the unmet medical ... received the Phase 2 portion of the Small Business ... (NCI) under the agency,s Streamlined Non-competing Award Procedures (SNAP). ...
... S. Blumberg, a Nobel Prize winning scientist and advisor to ... age of 85. Dr. Blumberg died after apparently suffering a ... Center at Moffett Field near San Jose, California. ... passing, and our condolences go out to his friends and ...
... (NASDAQ: CEPH ) said today in a ... Exchange Commission (SEC) that its Board of Directors has ... to remove and replace Cephalon,s current Board of Directors ...  On April 5, 2011, the Board rejected Valeant,s unsolicited ...
Cached Biology Technology:MabVax Therapeutics Receives $1.8 Million in a Phase 2 Small Business Innovation Research Program Award From the National Cancer Institute 2MabVax Therapeutics Receives $1.8 Million in a Phase 2 Small Business Innovation Research Program Award From the National Cancer Institute 3Nobel Winner Baruch Blumberg, Viral Genetics Advisor, Dies at 85 2Nobel Winner Baruch Blumberg, Viral Genetics Advisor, Dies at 85 3Cephalon Recommends Shareholders Reject Valeant Nominees 2Cephalon Recommends Shareholders Reject Valeant Nominees 3Cephalon Recommends Shareholders Reject Valeant Nominees 4Cephalon Recommends Shareholders Reject Valeant Nominees 5
(Date:3/23/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, announces its biometric payment technology, the Wocket® smart ... starting March 30 th . The ... New York markets. Gino ... our new ad campaign following the recent initial shipment of ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Hand Geometry - Global Strategic Business Report" report to ... for Hand Geometry in US$ Thousands. The report provides separate ... Japan , Europe , ... , and Rest of World. Annual estimates and ...
(Date:3/20/2015)... Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced the addition ... report to their offering. This report analyzes ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided for ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... a major long-term project to study coastal marine biodiversity ... possible by a $10 million donation from Suzanne and ... Capital Partners and philanthropist. The goal of the projectSmithsonian,s ... over a long period of time. The Tennenbaum ...
... 25, 2012 MedNet Solutions, a global life sciences ... and Advanced Clinical, a leading provider of clinical research ... joined the iMedNet ™ ... as an eClinical solution to support the research initiatives ...
... Biology professor Fei Wang and colleagues have created a ... blood stem cell, become the white blood cells important ... This approach offers new insights into the molecular mechanisms ... ability to treat myeloid diseases like leukemia, the researchers ...
Cached Biology News:Smithsonian launches global marine biodiversity project with $10 million donation 2Smithsonian launches global marine biodiversity project with $10 million donation 3Advanced Clinical Joins MedNet Solutions' iMedNet Partner Program 2A new technique to study how myeloids become white blood cells 2
...
Normal Bovine Serum; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin levels; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin lev...
12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry....
5(S)-HETE-d8 is used as an internal standard for the quantification of 5(S)-HETE by stable isotope dilution mass spectrometry....
Biology Products: